143 related articles for article (PubMed ID: 10786218)
1. [CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].
Zabrocka M; Woszczek G; Borowiec M; Rabe-Jabłońska J; Kowalski ML
Psychiatr Pol; 1999; 33(1):91-100. PubMed ID: 10786218
[TBL] [Abstract][Full Text] [Related]
2. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.
Ieiri I; Yamada S; Seto K; Morita T; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Pharmacopsychiatry; 2003 Sep; 36(5):192-6. PubMed ID: 14571354
[TBL] [Abstract][Full Text] [Related]
3. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
Buzková H; Pechandová K; Slanar O; Perlík F
Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
5. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 gene test in psychiatric patients and healthy volunteers.
Rasmussen JO; Christensen M; Svendsen JM; Skausig O; Hansen EL; Nielsen KA
Scand J Clin Lab Invest; 2006; 66(2):129-36. PubMed ID: 16537246
[TBL] [Abstract][Full Text] [Related]
7. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
8. Debrisoquine hydroxylase gene polymorphism in neurofibromatosis type 1.
Wundrack I; Sasiadek M; Blin N
Anticancer Res; 1997; 17(6D):4515-7. PubMed ID: 9494560
[TBL] [Abstract][Full Text] [Related]
9. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients.
González-Tejera G; Gaedigk A; Corey S
P R Health Sci J; 2010 Sep; 29(3):299-304. PubMed ID: 20799519
[TBL] [Abstract][Full Text] [Related]
11. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
12. [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
Grzesiak M; Beszłej A; Lebioda A; Jonkisz A; Dobosz T; Kiejna A
Psychiatr Pol; 2003; 37(3):433-44. PubMed ID: 13677973
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism of dextromethorphan oxidation in Polish population.
Skretkowicz J; Wojtczak A; Rychlik-Sych M
Acta Pol Pharm; 2008; 65(5):611-5. PubMed ID: 19051610
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.
Sosa-Macías M; Elizondo G; Flores-Pérez C; Flores-Pérez J; Bradley-Alvarez F; Alanis-Bañuelos RE; Lares-Asseff I
J Clin Pharmacol; 2006 May; 46(5):527-36. PubMed ID: 16638736
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 CYP2D6.
Wolf CR; Smith G
IARC Sci Publ; 1999; (148):209-29. PubMed ID: 10493260
[TBL] [Abstract][Full Text] [Related]
19. Debrisoquine hydroxylase (CYP2D6) and prostate cancer.
Febbo PG; Kantoff PW; Giovannucci E; Brown M; Chang G; Hennekens CH; Stampfer M
Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1075-8. PubMed ID: 9865424
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
